Combined Treatment of RFA and Sorafenib on Recurrent HCC

Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

Inclusion Criteria:

• recurrent HCC after curative resection
• without gender restriction
• age between 18 to 75 years
• The liver function showed no worse than Child-Pugh B
• tumor nodes were less than 5cm and no more than 3 nodules

Exclusion Criteria:

• Pregnancy patients
• With extrahepatic tumor or lymphnode metastasis
• Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava